ArticleFrontiers in oncology2022
ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- HNRNPC as a Novel Therapeutic Target for Ischemic Heart Disease: Evidence From Mendelian Randomization and Experimental Validation.Journal of the American Heart Association · 2026Article
- DLEU2 promotes the migration and invasion of papillary thyroid carcinoma cells through the ELAVL1/RCC2 axis.Functional & integrative genomics · 2026Article
- The impact of m6A modified cargo conveyed by exosomes on the tumor microenvironment.Discover oncology · 2026Review
- Genome-Wide Identification and Expression Analysis of mBiology · 2026Article
- [Overexpression of lncRNA SNHG12 promotes docetaxel resistance of prostate cancer cells by activating PI3K/AKT signalingNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- PDE4C stabilized by ELAVL1 promotes lymph node metastasis in papillary thyroid cancer.American journal of cancer research · 2026Article
- Article
- RNAtranslator: Modeling protein-conditional RNA design as sequence-to-sequence natural language translation.PLoS computational biology · 2025Article
- Emerging implications of N6-methyladenosine in prostate cancer progression and treatment.Cell death discovery · 2025Review
- The oncogenic role of SPOCK1 in lung carcinoma by promoting immune evasion and its related mechanisms.Cytotechnology · 2025Article
- Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma.Acta pharmacologica Sinica · 2025Article
- Identification of novel diagnostic and prognostic microRNAs in sarcoma on TCGA dataset: bioinformatics and machine learning approach.Scientific reports · 2025Article
- Review of the role and potential clinical value of m6A methylation modifications in the biological process of osteosarcoma.Frontiers in genetics · 2025Review
- Embryonic Lethal Abnormal Visual-Like Protein 1 Aggravates Caerulein-Induced AR42J Cell Injury and Macrophage M1 Polarization to Accelerate Acute Pancreatitis by Upregulating TRAF6.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2025Article
- Potential application of nanodelivery systems targeting ELAVL1 in prostate cancer treatment.Frontiers in oncology · 2025Review
- Whole-exome sequencing in Saudi colorectal cancer patients reveals distinct mutational patterns and population specific pathogenic variants.Frontiers in oncology · 2025Article
- Role and mechanism of COL3A1 in regulating the growth, metastasis, and drug sensitivity in cisplatin-resistant non-small cell lung cancer cells.Cancer biology & therapy · 2024Article
- Role of N6-methyladenosine RNA modification in cancer.MedComm · 2024Review
- Post-transcriptional regulation as a conserved driver of neural crest and cancer-cell migration.Current opinion in cell biology · 2024Review
- hsa_circ_0101050 regulated by ZC3H13 enhances tumorigenesis in papillary thyroid cancer via mHeliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-Methyladenosine (m6A) imbalance is an important factor in the occurrence and development of prostate cancer (PCa). Many m6A regulators have been found to be significantly dysregulated in PCa. ELAVL1 is an m6A binding protein that can promote the occurrence and development of tumors in an m6A-dependent manner. In this study, we found that most m6A regulators were significantly dysregulated in PCa, and some m6A regulators were associated with the progression-free interval. Mutations and copy number variations of these m6A regulators can alter their expression. However, ELAVL1 mutations were not found in PCa. Nevertheless, ELAVL1 upregulation was closely related to PCa proliferation. High ELAVL1 expression was also related to RNA metabolism. Further experiments showed that ELAVL1 interacted with other m6A regulators and that several m6A regulatory mRNAs have m6A sites that can be recognized by ELAVL1. Additionally, protein-protein interactions occur between ELAVL1 and other m6A regulators. Finally, we found that the dysregulation of ELAVL1 expression occurred in almost all tumors, and interactions between ELAVL1 and other m6A regulators also existed in almost all tumors. In summary, ELAVL1 is an important molecule in the development of PCa, and its interactions with other m6A regulators may play important roles in PCa progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.